Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 28 01 2022
accepted: 21 04 2022
entrez: 9 6 2022
pubmed: 10 6 2022
medline: 11 6 2022
Statut: epublish

Résumé

Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are critical in sustaining long-term protection and therefore may be an important factor when assessing pertussis immunity after vaccination. We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries. From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children (7-10y, n=53), adolescents (11-15y, n=66), young adults (20-34y, n=74), and older adults (60-70y, n=75). Memory B cells at baseline, day 28, and 1 year post-vaccination were measured by a pertussis toxin (Ptx), filamentous haemagglutinin (FHA), and pertactin (Prn) specific ELISpot assay. Antibody results measured previously were available for comparison. Furthermore, study participants were distributed into groups based on their baseline memory B cell frequencies, vaccine responses were monitored between these groups. Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one year post-booster compared to baseline. Highest frequencies at day 28 were found within adolescents (GM: 5, 21, and 13, for Ptx, FHA and Prn, respectively) and lowest within older adults (GM: 2, 9, and 3, respectively). Moderate to strong correlations between memory B cell frequencies at day 28 and antibody concentrations at day 28 and 1 year were observed for Prn. Memory B cell frequencies > 1 per 100,000 PBMCs at baseline were associated with significantly higher memory responses after 28 days and 1 year. An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory B cell activation seems weaker in older adults, which might reflect immunosenescence. Furthermore, the presence of circulating memory B cells at baseline positively affects memory B cell responses. This study was registered at www.clinicaltrialsregister.eu: No. 2016-003678-42.

Sections du résumé

Background
Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are critical in sustaining long-term protection and therefore may be an important factor when assessing pertussis immunity after vaccination.
Aim
We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries.
Materials and methods
From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children (7-10y, n=53), adolescents (11-15y, n=66), young adults (20-34y, n=74), and older adults (60-70y, n=75). Memory B cells at baseline, day 28, and 1 year post-vaccination were measured by a pertussis toxin (Ptx), filamentous haemagglutinin (FHA), and pertactin (Prn) specific ELISpot assay. Antibody results measured previously were available for comparison. Furthermore, study participants were distributed into groups based on their baseline memory B cell frequencies, vaccine responses were monitored between these groups.
Results
Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one year post-booster compared to baseline. Highest frequencies at day 28 were found within adolescents (GM: 5, 21, and 13, for Ptx, FHA and Prn, respectively) and lowest within older adults (GM: 2, 9, and 3, respectively). Moderate to strong correlations between memory B cell frequencies at day 28 and antibody concentrations at day 28 and 1 year were observed for Prn. Memory B cell frequencies > 1 per 100,000 PBMCs at baseline were associated with significantly higher memory responses after 28 days and 1 year.
Conclusions
An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory B cell activation seems weaker in older adults, which might reflect immunosenescence. Furthermore, the presence of circulating memory B cells at baseline positively affects memory B cell responses. This study was registered at www.clinicaltrialsregister.eu: No. 2016-003678-42.

Identifiants

pubmed: 35677044
doi: 10.3389/fimmu.2022.864674
pmc: PMC9168128
doi:

Substances chimiques

Pertussis Vaccine 0
Pertussis Toxin EC 2.4.2.31

Types de publication

Clinical Trial, Phase IV Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

864674

Informations de copyright

Copyright © 2022 Versteegen, Barkoff, Valente Pinto, van de Kasteele, Knuutila, Bibi, de Rond, Teräsjärvi, Sanders, de Zeeuw-Brouwer, Luoto, ten Hulscher, Clutterbuck, Sanders, Mertsola, Berbers, He, Kelly, Buisman and PERISCOPE Consortium.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Euro Surveill. 2019 Feb;24(7):
pubmed: 30782265
Vaccines (Basel). 2022 Jan 18;10(2):
pubmed: 35214595
Pediatrics. 2013 Jun;131(6):e1716-22
pubmed: 23690518
PLoS Pathog. 2013;9(7):e1003418
pubmed: 23935481
Nat Rev Immunol. 2015 Mar;15(3):149-59
pubmed: 25677494
Expert Rev Vaccines. 2019 May;18(5):439-455
pubmed: 30887849
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S119-S122
pubmed: 27838663
JAMA. 2012 Aug 1;308(5):454-6
pubmed: 22851107
Vaccines (Basel). 2021 Aug 07;9(8):
pubmed: 34452002
Emerg Microbes Infect. 2022 Dec;11(1):956-963
pubmed: 35286231
J Clin Microbiol. 2014 Oct;52(10):3549-57
pubmed: 25031439
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337481
Int Immunol. 2012 Mar;24(3):175-82
pubmed: 22281510
Expert Rev Vaccines. 2014 Sep;13(9):1081-106
pubmed: 25093268
BMC Med. 2016 Sep 01;14(1):121
pubmed: 27580649
Clin Infect Dis. 2000 Mar;30(3):534-9
pubmed: 10722440
Immun Ageing. 2019 Sep 13;16:25
pubmed: 31528180
Clin Transl Immunology. 2020 Aug 02;9(8):e1161
pubmed: 32765879
Stat Methods Med Res. 2017 Jun;26(3):1323-1340
pubmed: 25834090
Clin Vaccine Immunol. 2011 Jun;18(6):954-62
pubmed: 21508166
Front Immunol. 2018 Jan 24;9:51
pubmed: 29416544
J Immunol Methods. 2013 May 31;391(1-2):50-9
pubmed: 23454005
J Infect. 2016 Apr;72(4):468-77
pubmed: 26826518
Vaccine. 2018 Apr 19;36(17):2282-2287
pubmed: 29573876
Euro Surveill. 2017 Nov;22(47):
pubmed: 29183555
Clin Microbiol Infect. 2012 Sep;18(9):E340-6
pubmed: 22717007
Vaccines (Basel). 2020 May 15;8(2):
pubmed: 32429152
EBioMedicine. 2021 Mar;65:103247
pubmed: 33647770
Vaccine. 2011 Aug 5;29(34):5725-30
pubmed: 21669247
PLoS One. 2014 Jan 13;9(1):e85227
pubmed: 24454823
Clin Infect Dis. 2012 Nov 15;55(10):1434-5; author reply 1435-6
pubmed: 22871826
J Infect Dis. 2003 Sep 1;188(5):738-42
pubmed: 12934190
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S10-8
pubmed: 15876918
Clin Vaccine Immunol. 2013 Sep;20(9):1388-95
pubmed: 23825195
Pediatrics. 1999 Dec;104(6):e70
pubmed: 10586004
APMIS. 2021 Sep;129(9):556-565
pubmed: 34120372
Clin Exp Immunol. 2006 Jun;144(3):543-51
pubmed: 16734625
J Allergy Clin Immunol. 2020 May;145(5):1309-1321
pubmed: 32386655
Eur J Clin Microbiol Infect Dis. 1996 Oct;15(10):793-8
pubmed: 8950556
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 28289058
Vaccine. 2009 Dec 10;28(1):179-86
pubmed: 19799844
Vaccine. 2011 Feb 4;29(7):1431-7
pubmed: 21187178
Clin Vaccine Immunol. 2014 Sep;21(9):1301-8
pubmed: 25008903
Lancet Reg Health Eur. 2021 Sep 06;10:100196
pubmed: 34806066

Auteurs

Pauline Versteegen (P)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Alex-Mikael Barkoff (AM)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Marta Valente Pinto (M)

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Jan van de Kasteele (J)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Aapo Knuutila (A)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Sagida Bibi (S)

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Lia de Rond (L)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Johanna Teräsjärvi (J)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Katherine Sanders (K)

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Mary-Lène de Zeeuw-Brouwer (ML)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Raakel Luoto (R)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Hinke Ten Hulscher (H)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Elizabeth A Clutterbuck (EA)

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Elisabeth A M Sanders (EAM)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, Utrecht, Netherlands.

Jussi Mertsola (J)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Guy A M Berbers (GAM)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Qiushui He (Q)

Institute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.

Dominic F Kelly (DF)

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Anne-Marie Buisman (AM)

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH